Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H21N3O.ClH |
Molecular Weight | 331.84 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CCN1C2=C(C=CC=C2)N(C)C3=C(C=CC=C3)C1=O
InChI
InChIKey=RJPZIQRLRMWPRF-UHFFFAOYSA-N
InChI=1S/C18H21N3O.ClH/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22;/h4-11H,12-13H2,1-3H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H21N3O |
Molecular Weight | 295.3788 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://mentalhealthdaily.com/2014/08/18/tricyclic-antidepressants-list-tcas/
Curator's Comment: Description was created based on several sources, including
http://mentalhealthdaily.com/2014/08/18/tricyclic-antidepressants-list-tcas/
Dibenzepin is a tricyclic antidepressant of the dibenzo-epine group. It is a selective noradrenaline uptake inhibitor, which exhibits in vitro and in vivo imipramine-like effects. It binds strongly to histamine H1 receptors in the brain and, to a lesser extent, to cholinergic receptors. The pharmacological profile of dibenzepin corresponds widely to its biochemical properties: histamine antagonism, tetrabenazine antagonism, potentiation of various noradrenergic effects and anticholinergic effects. Dibenzepin is only available in European countries for the treatment of depression.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
|||
Target ID: CHEMBL2363064 Sources: http://www.kegg.jp/entry/D07812 |
|||
Target ID: CHEMBL2094109 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NOVERIL Approved UseNoveril (dibenzepin) is indicated for the treatment of depression |
PubMed
Title | Date | PubMed |
---|---|---|
Dibenzepin and amitriptyline in the treatment of depression. | 1971 May |
|
Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma. | 2002 |
|
Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations. | 2002 Feb |
|
Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. | 2003 Dec |
|
Comparison of trazodone, diazepame and dibenzepine influences on rat brain beta-endorphins content. | 2007 Aug |
|
Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. | 2008 Mar |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4155170
In adult patients, treatment should begin with Noveril (dibenzepin) 240 mg tablets, the daily dose being given as a single dose or in 2 divided dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18048694
Dibenzepin blocked calcium current in enzymatically isolated rat ventricular myocytes with IC(50) values of 364 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:37 GMT 2023
by
admin
on
Fri Dec 15 15:11:37 GMT 2023
|
Record UNII |
JLN0273S4Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000087922
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL1442422
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
169412
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
JLN0273S4Z
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
C084605
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
DTXSID5048421
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
SUB01659MIG
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
m4282
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
206-255-6
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
9418
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
315-80-0
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
C169906
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | |||
|
236807
Created by
admin on Fri Dec 15 15:11:37 GMT 2023 , Edited by admin on Fri Dec 15 15:11:37 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |